Molecular Cancer Therapeutics Chemical and Biological Aspects of Inflammation and Cancer Targeting the PI3-Kinase Pathway in Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bottone, F. G.
Right arrow Articles by Eling, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bottone, F. G., Jr.
Right arrow Articles by Eling, T. E.
Mol Cancer Ther. 2005;4:693-703
© 2005 American Association for Cancer Research

The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3)

Frank G. Bottone, Jr.1, Yuseok Moon1, Jong Sik Kim1, Brenda Alston-Mills2, Minako Ishibashi1 and Thomas E. Eling1

1 Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina and 2 Department of Animal Sciences, North Carolina State University, Raleigh, North Carolina

Requests for reprints: Thomas Eling, Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, P.O. Box 12233, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709. Phone: 919-541-3911; Fax: 919-541-0146. E-mail: Eling{at}niehs.nih.gov

We previously showed that nonsteroidal anti-inflammatory drugs (NSAID) such as sulindac sulfide, which has chemopreventive activity, modulate the expression of several genes detected by microarray analysis. Activating transcription factor 3 (ATF3) was selected for further study because it is a transcription factor involved in cell proliferation, apoptosis, and invasion, and its expression is repressed in human colorectal tumors as compared with normal adjacent tissue. In this report, we show that ATF3 mRNA and protein expression are up-regulated in HCT-116 human colorectal cancer cells following treatment with NSAIDs, troglitazone, diallyl disulfide, and resveratrol. To ascertain the biological significance of ATF3, we overexpressed full-length ATF3 protein in the sense and antisense orientations. Overexpression of ATF3 in the sense orientation decreased focus formation in vitro and reduced the size of mouse tumor xenografts by 54% in vivo. Conversely, overexpression of antisense ATF3 was protumorigenic in vitro, however, not in vivo. ATF3 in the sense orientation did not modulate apoptosis, indicating another mechanism is involved. With microarray analysis, several genes relating to invasion and metastasis were identified by ATF3 overexpression and were confirmed by real-time reverse transcription-PCR, and several of these genes were modulated by sulindac sulfide, which inhibited invasion in these cells. Furthermore, overexpression of ATF3 inhibited invasion to a similar degree as sulindac sulfide treatment, whereas antisense ATF3 increased invasion. In conclusion, ATF3 represents a novel mechanism in which NSAIDs exert their anti-invasive activity, thereby linking ATF3 and its gene regulatory activity to the biological activity of these compounds.


Key Words: Colorectal cancer • NSAIDs • Cyclooxygenase • ATF3

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 12/16/04; revised 1/24/05; accepted 3/ 2/05.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
C. Moser, S. A. Lang, S. Kainz, A. Gaumann, S. Fichtner-Feigl, G. E. Koehl, H. J. Schlitt, E. K. Geissler, and O. Stoeltzing
Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo
Mol. Cancer Ther., November 1, 2007; 6(11): 2868 - 2878.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. D. Cho, K. Yoon, S. Chintharlapalli, M. Abdelrahim, P. Lei, S. Hamilton, S. Khan, S. K. Ramaiah, and S. Safe
Nur77 Agonists Induce Proapoptotic Genes and Responses in Colon Cancer Cells through Nuclear Receptor-Dependent and Nuclear Receptor-Independent Pathways
Cancer Res., January 15, 2007; 67(2): 674 - 683.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Bandyopadhyay, Y. Wang, R. Zhan, S. K. Pai, M. Watabe, M. Iiizumi, E. Furuta, S. Mohinta, W. Liu, S. Hirota, et al.
The Tumor Metastasis Suppressor Gene Drg-1 Down-regulates the Expression of Activating Transcription Factor 3 in Prostate Cancer
Cancer Res., December 15, 2006; 66(24): 11983 - 11990.
[Abstract] [Full Text] [PDF]


Home page
Microbiol. Mol. Biol. Rev.Home page
M. A. Garcia, J. Gil, I. Ventoso, S. Guerra, E. Domingo, C. Rivas, and M. Esteban
Impact of Protein Kinase PKR in Cell Biology: from Antiviral to Antiproliferative Action
Microbiol. Mol. Biol. Rev., December 1, 2006; 70(4): 1032 - 1060.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. Cebrian, P. D. Pharoah, S. Ahmed, S. Ropero, M. F. Fraga, P. L. Smith, D. Conroy, R. Luben, B. Perkins, D. F. Easton, et al.
Genetic variants in epigenetic genes and breast cancer risk
Carcinogenesis, August 1, 2006; 27(8): 1661 - 1669.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Guerra, L. A. Lopez-Fernandez, M. A. Garcia, A. Zaballos, and M. Esteban
Human Gene Profiling in Response to the Active Protein Kinase, Interferon-induced Serine/threonine Protein Kinase (PKR), in Infected Cells: INVOLVEMENT OF THE TRANSCRIPTION FACTOR ATF-3 IN PKR-INDUCED APOPTOSIS
J. Biol. Chem., July 7, 2006; 281(27): 18734 - 18745.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Lu, C. D. Wolfgang, and T. Hai
Activating Transcription Factor 3, a Stress-inducible Gene, Suppresses Ras-stimulated Tumorigenesis
J. Biol. Chem., April 14, 2006; 281(15): 10473 - 10481.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
F. G. Bottone Jr., Y. Moon, B. Alston-Mills, and T. E. Eling
Transcriptional Regulation of Activating Transcription Factor 3 Involves the Early Growth Response-1 Gene
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 668 - 677.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Ohuchida, K. Mizumoto, N. Ishikawa, K. Fujii, H. Konomi, E. Nagai, K. Yamaguchi, M. Tsuneyoshi, and M. Tanaka
The Role of S100A6 in Pancreatic Cancer Development and Its Clinical Implication as a Diagnostic Marker and Therapeutic Target
Clin. Cancer Res., November 1, 2005; 11(21): 7785 - 7793.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Moon, F. G. Bottone Jr., M. F. McEntee, and T. E. Eling
Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1
Mol. Cancer Ther., October 1, 2005; 4(10): 1551 - 1558.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.